Cécile Charles1, Catherine Bungener2, Darius Razavi3, Christine Mateus4, Emilie Routier4, Emilie Lanoy5, Michèle Verschoore6, Caroline Robert4, Sarah Dauchy7. 1. Psycho-Oncology Unit, Gustave Roussy, Villejuif, France; Laboratory of Psychopathology and Health Processes, EA 4057, Psychology Institute, Paris Descartes University-Sorbonne Paris Cité, Boulogne-Billancourt, France. Electronic address: cecile.charles@gustaveroussy.fr. 2. Laboratory of Psychopathology and Health Processes, EA 4057, Psychology Institute, Paris Descartes University-Sorbonne Paris Cité, Boulogne-Billancourt, France. 3. Psychosomatic and Psycho-Oncology Research Unit, University of Brussels-Psycho-Oncology Clinic, Jules Bordet Institute, Brussels, Belgium. 4. Dermatology Service, Gustave Roussy Cancer Campus Grand-Paris-Sud, Villejuif, France. 5. Department of Biostatistics and Epidemiology, Gustave Roussy, Villejuif, France. 6. Department of Research and Innovation, L'Oreal, Paris, France. 7. Psycho-Oncology Unit, Gustave Roussy, Villejuif, France.
Abstract
BACKGROUND: Investigations about the impact of dermatologic adverse events on quality of life in the context of targeted therapies are quite recent and results vary in some dimensions. This article aims to summarize the existing data and to clarify needs in terms of clinical management and future research. METHODS: A literature review was done with Pubmed, Medline, Scopus and PsycInfo databases and it combined the empirical studies published in English and in French over the past ten years. RESULTS AND CONCLUSIONS: Dermatologic adverse events globally have a low to moderate impact on quality of life, mainly in the physical and emotional domains. Reasons for inter-individual variations in adjustment and long-term impact are still not well known. Making quality of life assessments systematic, making early referrals of patients to dermatology consultations and giving more attention to individual experience were identified as measures that could help prevent deterioration in quality of life.
BACKGROUND: Investigations about the impact of dermatologic adverse events on quality of life in the context of targeted therapies are quite recent and results vary in some dimensions. This article aims to summarize the existing data and to clarify needs in terms of clinical management and future research. METHODS: A literature review was done with Pubmed, Medline, Scopus and PsycInfo databases and it combined the empirical studies published in English and in French over the past ten years. RESULTS AND CONCLUSIONS: Dermatologic adverse events globally have a low to moderate impact on quality of life, mainly in the physical and emotional domains. Reasons for inter-individual variations in adjustment and long-term impact are still not well known. Making quality of life assessments systematic, making early referrals of patients to dermatology consultations and giving more attention to individual experience were identified as measures that could help prevent deterioration in quality of life.
Authors: Jaxon J Vallely; Kathryn E Hudson; Susan C Locke; Steven P Wolf; Gregory P Samsa; Amy P Abernethy; Thomas W LeBlanc Journal: Support Care Cancer Date: 2019-02-14 Impact factor: 3.603
Authors: Rebecca L Edwards; Christine Andan; Rajesh V Lalla; Mario E Lacouture; Dennis O'Brien; Lecia V Sequist Journal: Clin J Oncol Nurs Date: 2018-10-01 Impact factor: 1.283
Authors: Jaewon Lee; Jin Lim; Jong Seo Park; Miso Kim; Tae-Yong Kim; Tae Min Kim; Kyung-Hun Lee; Bhumsuk Keam; Sae-Won Han; Je-Ho Mun; Kwang Hyun Cho; Seong Jin Jo Journal: Cancer Res Treat Date: 2017-12-14 Impact factor: 4.679
Authors: J Wu; D Liu; M Offin; B T Li; M E Lacouture; C Lezcano; J M Torrisi; S Brownstein; D M Hyman; M M Gounder; W Abida; A Drilon; J J Harding; R J Sullivan; F Janku; D Welsch; M Varterasian; A Groover Journal: Invest New Drugs Date: 2021-01-03 Impact factor: 3.651